According to the rating criteria, 8 (80%) of the 10 benign prostatic hyperplasia samples were classified as positive for SFRP1 expression and 2 (20%) were classified as negative, whereas in tumor samples, SFRP1 expression significantly decreased with 36 (59%) positive and 25 (41%) negative. The gene discussed is SFRP1; the disease is neoplasm.